Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 2
2012 1
2014 1
2015 1
2016 2
2017 5
2018 2
2019 1
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

19 results
Results by year
Filters applied: . Clear all
Page 1
New therapeutic targets in pancreatic cancer.
Lai E, Puzzoni M, Ziranu P, Pretta A, Impera V, Mariani S, Liscia N, Soro P, Musio F, Persano M, Donisi C, Tolu S, Balconi F, Pireddu A, Demurtas L, Pusceddu V, Camera S, Sclafani F, Scartozzi M. Lai E, et al. Among authors: Pusceddu V. Cancer Treat Rev. 2019 Dec;81:101926. doi: 10.1016/j.ctrv.2019.101926. Epub 2019 Nov 11. Cancer Treat Rev. 2019. PMID: 31739115 Review.
Multimodal treatment of resectable pancreatic ductal adenocarcinoma.
Silvestris N, Brunetti O, Vasile E, Cellini F, Cataldo I, Pusceddu V, Cattaneo M, Partelli S, Scartozzi M, Aprile G, Casadei Gardini A, Morganti AG, Valentini V, Scarpa A, Falconi M, Calabrese A, Lorusso V, Reni M, Cascinu S. Silvestris N, et al. Among authors: Pusceddu V. Crit Rev Oncol Hematol. 2017 Mar;111:152-165. doi: 10.1016/j.critrevonc.2017.01.015. Epub 2017 Feb 4. Crit Rev Oncol Hematol. 2017. PMID: 28259290 Review.
BRAF-mutant colorectal cancer, a different breed evolving.
Lai E, Pretta A, Impera V, Mariani S, Giampieri R, Casula L, Pusceddu V, Coni P, Fanni D, Puzzoni M, Demurtas L, Ziranu P, Faa G, Scartozzi M. Lai E, et al. Among authors: Pusceddu V. Expert Rev Mol Diagn. 2018 Jun;18(6):499-512. doi: 10.1080/14737159.2018.1470928. Epub 2018 May 9. Expert Rev Mol Diagn. 2018. PMID: 29708446 Review.
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?
Giampieri R, Caporale M, Pietrantonio F, De Braud F, Negri FV, Giuliani F, Pusceddu V, Demurtas L, Restivo A, Fontanella C, Aprile G, Cascinu S, Scartozzi M. Giampieri R, et al. Among authors: Pusceddu V. Crit Rev Oncol Hematol. 2016 Apr;100:99-106. doi: 10.1016/j.critrevonc.2016.02.005. Epub 2016 Feb 12. Crit Rev Oncol Hematol. 2016. PMID: 26907512 Review.
Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link?
Pani F, Massidda M, Pusceddu V, Puzzoni M, Massa E, Madeddu C, Scartozzi M, Mariotti S. Pani F, et al. Among authors: Pusceddu V. Eur J Endocrinol. 2017 Jul;177(1):85-92. doi: 10.1530/EJE-17-0231. Epub 2017 May 3. Eur J Endocrinol. 2017. PMID: 28468766 Clinical Trial.
Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer.
Rihawi K, Giampieri R, Scartozzi M, Pusceddu V, Bonotto M, Fasola G, Cascinu S, Aprile G. Rihawi K, et al. Among authors: Pusceddu V. Expert Opin Investig Drugs. 2015;24(9):1185-98. doi: 10.1517/13543784.2015.1054479. Epub 2015 Jun 4. Expert Opin Investig Drugs. 2015. PMID: 26044119 Review.
The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy.
Giampieri R, Restivo A, Pusceddu V, Del Prete M, Maccaroni E, Bittoni A, Faloppi L, Andrikou K, Bianconi M, Cabras F, Berardi R, Zorcolo L, Scintu F, Cascinu S, Scartozzi M. Giampieri R, et al. Among authors: Pusceddu V. Clin Colorectal Cancer. 2017 Mar;16(1):38-43. doi: 10.1016/j.clcc.2016.07.011. Epub 2016 Aug 4. Clin Colorectal Cancer. 2017. PMID: 27576095
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis.
Giampieri R, Prete MD, Prochilo T, Puzzoni M, Pusceddu V, Pani F, Maccaroni E, Mascia R, Baleani MG, Meletani T, Berardi R, Lanzillo AM, Mariotti S, Zaniboni A, Cascinu S, Scartozzi M. Giampieri R, et al. Among authors: Pusceddu V. Sci Rep. 2017 Apr 5;7:45703. doi: 10.1038/srep45703. Sci Rep. 2017. PMID: 28378839 Free PMC article.
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
Demurtas L, Puzzoni M, Giampieri R, Ziranu P, Pusceddu V, Mandolesi A, Cremolini C, Masi G, Gelsomino F, Antoniotti C, Loretelli C, Meriggi F, Zaniboni A, Falcone A, Cascinu S, Scartozzi M. Demurtas L, et al. Among authors: Pusceddu V. Br J Cancer. 2017 Jul 25;117(3):315-321. doi: 10.1038/bjc.2017.178. Epub 2017 Jun 20. Br J Cancer. 2017. PMID: 28632725 Free PMC article.
Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer.
Lai E, Liscia N, Donisi C, Mariani S, Tolu S, Pretta A, Persano M, Pinna G, Balconi F, Pireddu A, Impera V, Dubois M, Migliari M, Spanu D, Saba G, Camera S, Musio F, Ziranu P, Puzzoni M, Demurtas L, Pusceddu V, Dettori M, Massa E, Atzori F, Dessì M, Astara G, Madeddu C, Scartozzi M. Lai E, et al. Among authors: Pusceddu V. Cancers (Basel). 2020 May 13;12(5):1214. doi: 10.3390/cancers12051214. Cancers (Basel). 2020. PMID: 32413973 Free PMC article. Review.
19 results
Jump to page
Feedback